Illumina, Inc. $ILMN Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA cut its stake in Illumina, Inc. (NASDAQ:ILMN) by 6.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 302,352 shares of the life sciences company’s stock after selling 21,078 shares during the period. Pictet Asset Management Holding SA’s holdings in Illumina were worth $40,417,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Board of the Pension Protection Fund bought a new position in shares of Illumina during the fourth quarter worth about $26,000. Creative Capital Management Investments LLC lifted its holdings in Illumina by 160.0% during the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after buying an additional 120 shares during the last quarter. TD Waterhouse Canada Inc. acquired a new position in shares of Illumina in the 4th quarter worth approximately $26,000. Quent Capital LLC bought a new stake in shares of Illumina in the 3rd quarter valued at approximately $29,000. Finally, Quarry LP acquired a new stake in shares of Illumina during the 3rd quarter valued at approximately $32,000. Institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $120.37 on Thursday. Illumina, Inc. has a 1-year low of $73.86 and a 1-year high of $155.53. The firm has a market capitalization of $18.29 billion, a PE ratio of 22.09, a P/E/G ratio of 2.46 and a beta of 1.49. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72. The business’s fifty day moving average price is $125.55 and its two-hundred day moving average price is $126.43.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.26 by $0.09. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The company’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, research analysts expect that Illumina, Inc. will post 5.12 EPS for the current year.

Insider Activity at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the sale, the senior vice president owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 2.90% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on ILMN. Evercore set a $150.00 price objective on shares of Illumina in a report on Friday, February 6th. Canaccord Genuity Group raised their price target on shares of Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a research report on Monday, January 26th. Piper Sandler decreased their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a report on Monday, February 9th. Robert W. Baird set a $137.00 price objective on shares of Illumina in a research report on Friday, February 6th. Finally, UBS Group reissued a “neutral” rating and issued a $135.00 target price on shares of Illumina in a report on Friday, February 6th. Six equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Illumina presently has an average rating of “Hold” and an average target price of $129.69.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.